Francis JA, Elit L, Coakley N, MacKay H And Gynecologic Cancer Disease Site Group. Systematic therapy for recurrent epithelial ovarian cancer: a clinical practice guideline. Current Oncology. 2017;24(6):e540-e546 doi: 10.3747/co.24.3824
Elit L, Fyles A, Gu C, Pond G, D’Souza D, Samant R, Anthes M, Thomas G, Filion M, Arsenault J, Dayes I, Whelan T, Gulenchyn K, Metser U, Dhamanaskar K, Levine M. Impact of Positron Emission Tomography (PET) imaging in Women with locally advanced cervical cancer: a Randomized trial. JAMA Open Network 2018:1(5):e182081 doi:10.1001/jamanetworkopen.2018.2081 14Sep2018 pp1-13
Shakeel, S., Elit, L., Akhtar-Danesh, N., Schneider, L. and Finley, C., 2017. Care Delivery Patterns, Processes, and Outcomes for Primary Ovarian Cancer Surgery: A Population-Based Review Using a National Administrative Database. Journal of Obstetrics and Gynaecology Canada, 39(1), pp.25-33.
Barbera, L., Gien, L.T., Sutradhar, R., Thomas, G., Covens, A., Elit, L., Fyles, A., Rakovitch, E., Liu, Y. and Khalifa, M., 2017. The Added Value of Pathology Review in Vulvar Cancer: Results From a Population-based Cohort Study. International Journal of Gynecological Pathology, 36(2), pp.107-110.
McGee, J., Panabaker, K., Leonard, S., Ainsworth, P., Elit, L. and Shariff, S.Z., 2017. Genetics Consultation Rates Following a Diagnosis of High-Grade Serous Ovarian Carcinoma in the Canadian Province of Ontario. International Journal of Gynecological Cancer, 27(3), pp.437-443.
Serrano Aybar, P.E., Dhamanaskar, K., Elit, L., Parpia, S., Linkins, L.A., Simunovic, M., Ruo, L., Bhandari, M. and Levine, M.N., 2017. Incidence of venous thromboembolic events following major pelvic and abdominal surgery for cancer. Journal of Clinical Oncology, 35(4) Suppl, pp. 478-478.
Elit, L., 2016. Cervical cancer screening in women over 65. PRO: Are we asking the right question?. Gynecologic Oncology, 142(3), pp.381-382.
Bezanson, K., Nouvet, E., Hunt, M., de Laat, S., Elit, L., Bernard, C. and Schwartz, L., 2016. D08-C The Place of Palliative Care in Humanitarian Response. Journal of Pain and Symptom Management, 52(6), pp.e34-e35.
Mackay, H., Soobrian, J., Murphy, J., Elit, L., Milosevic, M.F., Gollnow, A., Ross, J. and Holloway, C., 2016. Pathway map development as an approach to identifying priority areas for quality improvement in Ontario. Journal of Clinical Oncology, 34(7) Suppl pp. 108-108.
Le, T., Kennedy, E.B., Dodge, J. and Elit, L., 2016. Follow-up of patients who are clinically disease-free after primary treatment for fallopian tube, primary peritoneal, or epithelial ovarian cancer: a Program in Evidence-Based Care guideline adaptation. Current Oncology, 23(5), p.343.
Elit, L., Kennedy, E.B., Fyles, A. and Metser, U., 2016. Follow-up for cervical cancer: a Program in Evidence- Based Care systematic review and clinical practice guideline update. Current Oncology, 23(2), p.109.
McDonald, H., Charles, C., Elit, L. and Gafni, A., 2016. Challenges in striving to simultaneously achieve multiple resource allocation goals: the pan-Canadian Oncology Drug Review (pCODR) example. Journal of Market Access & Health Policy, 4.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Pond, G., Elit, L. and Kong, I., 2016. The Pathologic and Treatment Factors Associated With Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. International Journal of Radiation Oncology• Biology• Physics, 96(2), p.E315.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Pond, G., Memon, S., Elit, L. and Kong, I., 2016. 228: Pathologic and Treatment Factors Associated with Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. Radiotherapy and Oncology, 120, p.S83.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Elit, L. and Kong, I., 2016. Outcomes of Stage IA Serous Endometrial Adenocarcinoma. Brachytherapy, 15, pp.S111-S112.
Voruganti, T., Moineddin, R., Jembere, N., Elit, L., Grunfeld, E. and Lofters, A.K., 2016. Comparing stage of diagnosis of cervical cancer at presentation in immigrant women and long-term residents of Ontario: a retrospective cohort study. CMAJ open, 4(3), p.E424.
Elit, L., 2015. Wait times from diagnosis to treatment in cancer. Journal of gynecologic oncology, 26(4), pp.246-248.
McDonald, H., Charles, C., Elit, L. and Gafni, A., 2015. Is there an economic rationale for cancer drugs to have a separate reimbursement review process for resource allocation purposes?. Pharmacoeconomics, 33(3), pp.235-
241.
Jimenez, W., Maxwell, J., Daya, D., Sur, M., Elit, L., Eiriksson, L., Reade, C. and Lytwyn, A., 2015. UNDIFFERENTIATED ENDOMETRIAL CANCER, A DIFFERENT ENTITY WITH AN AGGRESSIVE BEHAVIOR: IGCS-0060 Uterine Cancer, including Sarcoma. International Journal of Gynecological Cancer, 25, p.69.
Fung-Kee-Fung, M., Kennedy, E.B., Biagi, J., Colgan, T., D’Souza, D., Elit, L.M., Hunter, A., Irish, J., McLeod, R. and Rosen, B., 2015. The optimal organization of gynecologic oncology services: a systematic review. Current Oncology, 22(4), p.e282.
Elit L, Pond G, Seow H. Letter to the Editor. Wait Time and Survival for Type 1 Endometrial Cancer. Obstetrics and Gynecology 2015:125(6):
Kroft, J., Li, Q., Saskin, R., Elit, L., Bernardini, M.Q. and Gien, L.T., 2015. Trends over time in the use of laparoscopic hysterectomy for the treatment of endometrial cancer. Gynecologic oncology, 138(3), pp.536-541.
Elit, L.M., Pond, G. and Seow, H., 2015. Time interval between endometrial biopsy and surgical staging for type I endometrial cancer: association between tumor characteristics and survival outcome. Obstetrics & Gynecology, 125(6), pp.1497-1498.
McDonald, H., Charles, C., Elit, L. and Gafni, A., 2015. The Silence in Hoch et al.’s Commentary about the Rationale for and Objective (s) of Canada’s Separate HTA Process for Cancer Drugs: The Importance of Transparency and Accountability when Allocating Taxpayers’ Dollars. PharmacoEconomics, 33(8), pp.883-886.
Elit, L.M., Fyles, A.W., Gu, C.S., Pond, G.R., D'Souza, D., Samant, R., Anthes, M., Thomas, G., Fillion, M., Arsenault, J. and Dayes, I., 2015. The role of PET-CT in treatment decision making for women with locally advanced cervical cancer. Journal of Clinical Oncology, 33(15) Suppl, pp. 5523-5523.
Murphy, J., Varela, N.P., Elit, L., Lytwyn, A., Yudin, M., Shier, M., Wu, V. and El-Khatib, S., 2015. The organization of colposcopy services in Ontario: recommended framework. Current Oncology, 22(4), p.287.
Elit, L., Charles, C.A. and Gafni, A., 2015. Oncologists’ Perceptions of Recurrent Ovarian Cancer Patients’ Preference for Participation in Treatment Decision Making and Strategies for When and How to Involve Patients in This Process. International Journal of Gynecological Cancer, 25(9), pp.1717-1723.
Akhtar-Danesh, N., Elit, L. and Lytwyn, A., 2015. Further Insights Into Long-Term Trends in Relative Survival of Vulvar Cancer Patients: A Population-Based Study. International Journal of Gynecological Cancer, 25(1), pp.125-130.
Fung-Kee-Fung, M., Kennedy, E.B., Biagi, J., Colgan, T., D’Souza, D., Elit, L.M., Hunter, A., Irish, J., McLeod, R. and Rosen, B., 2015. An organizational guideline for gynecologic oncology services. International Journal of Gynecological Cancer, 25(4), pp.551-558.
Elit LM, Charles CA, Gafni A. Oncologists’ perceptions of recurrent ovarian cancer patients’ preference for participation in treatment decision and making and strategies for when and how to involve patients in this process. IJGC, 25(9), 1717-23.
Elit, L. and Reade, C.J., 2015. Recommendations for follow-up care for gynecologic cancer survivors. Obstetrics & Gynecology, 126(6), pp.1207-1214.
Hirte, H., Kennedy, E.B., Elit, L. and Fung, M.F.K., 2015. Systemic therapy for recurrent, persistent, or metastatic cervical cancer: a clinical practice guideline. Current Oncology, 22(3), p.211.
Gien, L.T., Sutradhar, R., Thomas, G., Covens, A., Elit, L., Rakovitch, E., Fyles, A., Khalifa, M.A., Liu, Y. and Barbera, L., 2015. Patient, tumor, and health system factors affecting groin node dissection rates in vulvar carcinoma: A population-based cohort study. Gynecologic oncology, 139(3), pp.465-470.
Elit, L. and Reade, C.J., 2015. Recomendaciones para la Atención de Seguimiento a Sobrevivientes de Cáncer Ginecológico. Obstet Gynecol, 126, pp.1207-1214.
Prummel, M.V., Young, S.W., Candido, E., Nishri, D., Elit, L. and Marrett, L.D., 2014. Cervical cancer incidence in ontario women: differing sociodemographic gradients by morphologic type (adenocarcinoma versus squamous cell). International Journal of Gynecological Cancer, 24(7), pp.1341-1346.
Tsoref, D., Welch, S., Lau, S., Biagi, J., Tonkin, K., Martin, L.A., Ellard, S., Ghatage, P., Elit, L., Mackay, H.J. and Allo, G., 2014. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. Gynecologic oncology, 135(2), pp.184-189.
Elit, L., and Hirte, H., 2014. Novel Targeted Therapies in Ovarian Cancer. Journal of Cancer Science and Therapy, 6 pp.350-362.
Elit, L.M., Pond, G. and Seow, H.Y., 2014. Reply to J. Menczer. Journal of Clinical Oncology, 32(19), pp.2114-2114.
Chernesky, M., Jang, D., Gilchrist, J., Elit, L., Lytwyn, A., Smieja, M., Dockter, J., Getman, D., Reid, J. and Hill, C., 2014. Evaluation of a new APTIMA specimen collection and transportation kit for high-risk human papillomavirus E6/E7 messenger RNA in cervical and vaginal samples. Sexually transmitted diseases, 41(6), pp.365-368.
Gien, L.T., Sutradhar, R., Thomas, G., Covens, A., Elit, L., Rakovitch, E., Fyles, A., Khalifa, M.A., Liu, Y. and Barbera, L., 2017. Does a groin node dissection in vulvar cancer affect groin recurrence and overall survival?: Results from a population-based cohort study. Gynecologic oncology, 144(2), pp.318-323.
Elit, L., 2014. Cervical cancer in the older woman. Maturitas, 78(3), pp.160-167.
Elit, L.M. and Hirte, H., 2014. Management of advanced or recurrent cervical cancer: chemotherapy and beyond. Expert review of anticancer therapy, 14(3), pp.319-332.
Elit, L., 2014. Role of cervical screening in older women. Maturitas, 79(4), pp.413-420.
Chernesky, M., Jang, D., Gilchrist, J., Randazzo, J., Elit, L., Lytwyn, A., Smieja, M., Reid, J. and Hill, C., 2014. Ease and Comfort of Cervical and Vaginal Sampling for Chlamydia trachomatis and Trichomonas vaginalis with a New Aptima Specimen Collection and Transportation Kit. Journal of clinical microbiology, 52(2), pp.668-670.
Vicus, D., Sutradhar, R., Lu, Y., Elit, L., Kupets, R., Paszat, L. and Investigators of the Ontario Cancer Screening Research Network, 2014. The association between cervical cancer screening and mortality from cervical cancer: A population based case–control study. Gynecologic oncology, 133(2), pp.167-171.
Elit, L.M., O'Leary, E.M., Pond, G.R. and Seow, H.Y., 2013. Impact of wait times on survival for women with uterine cancer. Journal of Clinical Oncology, 32(1), pp.27-33.
Akhtar-Danesh, N., Elit, L. and Lytwyn, A., 2014. Trends in incidence and survival of women with invasive vulvar cancer in the United States and Canada: a population-based study. Gynecologic oncology, 134(2), pp.314-318.
Kroft, J., Li, Q., Saskin, R., Elit, L., Bernardini, M.Q. and Gien, L.T., 2014. Trends over Time and Regional Variation in the Use of Laparoscopic Hysterectomy for the Treatment of Endometrial Cancer in the Province of Ontario, Canada. Journal of Minimally Invasive Gynecology, 21(6), p.S10.
Hunt M, Schwartz L, Pringle J, Boulanger R, Nouvet E, O'Mathúna D,, Arya N, Bernard C, Beukeboom C, Calain P, de Laat S, Eckenwiler L, Elit L, Fraser V, Gillespie LA, Johnson K, Meagher R, Nixon S, Olivier C, Pakes B, Redwood-Campbell L, Reis A, Renaldi T, Singh J, Smith M, Von Schreeb J A research agenda for humanitarian health ethics. PLoS Curr. 12;6
Barbera, L., Gien, L.T., Sutradhar, R., Thomas, G.M., Covens, A.L., Elit, L.M., Fyles, A., Rakovitch, E. and Khalifa, M., 2014. Frequency of missing data from vulvar carcinoma pathology reports: Results from a population-based cohort. Gynecologic Oncology, 133, p.192.
Broomfield, J.A., Hirte, H., Elit, L., Kong, I., Patel, M., Voruganti, S., Smith, C., Chow, T. and Swaminath, A., 2014. Stereotactic Ablative Radiation Therapy for Gynecological Malignancies in the Oligometastatic Setting. International Journal of Radiation Oncology• Biology• Physics, 90(1), p.S908.
Stark, D., Nankivell, M., Pujade-Lauraine, E., Kristensen, G., Elit, L., Stockler, M., Hilpert, F., Cervantes, A., Brown, J., Lanceley, A. and Velikova, G., 2013. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. The lancet oncology, 14(3), pp.236-243.
Reade, C.J., Riva, J.J., Busse, J.W., Goldsmith, C.H. and Elit, L., 2013. Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. Gynecologic oncology, 130(3), pp.674-681.
Eiriksson, L., Reade, C.J. and Elit, L., 2013. Meeting highlights: International Gynecologic Cancer Society (IGCS 2012). Gynecologic oncology, 128(1), pp.12-14.
Finch, A., Metcalfe, K.A., Chiang, J., Elit, L., McLaughlin, J., Springate, C., Esplen, M.J., Demsky, R., Murphy, J., Rosen, B. and Narod, S.A., 2013. The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation. Psycho-Oncology, 22(1), pp.212-219.
Elit, L., Saskin, R., Raut, R., Elliott, L., Murphy, J. and Marrett, L., 2013. Sociodemographic factors associated with cervical cancer screening coverage and follow-up of high grade abnormal results in a population-based cohort. Gynecologic oncology, 128(1), pp.95-100.
Elit, L. and Hirte, H., 2013. Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options. OncoTargets Ther, 6, pp.107-18.
Chernesky, M., Jang, D., Gilchrist, J., Randazzo, J., Elit, L., Lytwyn, A., Smieja, M., Reid, J. and Hill, C., 2013. Ease and comfort of a new APTIMA specimen collection and transportation kit with cervical and vaginal sampling for Chlamydia trachomatis and Trichomonas vaginalis. Journal of clinical microbiology, pp.JCM-02923.
Elit, L., Charles, C., Gafni, A., Gold, I., Ranford, J. and Gold, S.T., 2013. How oncologists communicate information to women with recurrent ovarian cancer in the context of treatment decision making in the medical encounter. Gynecologic Oncology, 130(1), p.e112.
Bell, K., Scott, M., Pond, G., Piccinin, C. and Amer, M., 2013. Genetic Counselling Referral Rates and Uptake of BRCA1 and BRCA2 Testing among Women Diagnosed with Serous Ovarian Cancer in a Tertiary Care Cancer Centre. J Genet Syndr Gene Ther, 4(156), p.2.
Ray-Coquard, I., Haluska, P., O'Reilly, S., Cottu, P.H., Elit, L., Provencher, D.M., Beckmann, M.W., Bosserman, L.D., Jacod, S., Houe, V. and Loberg, R.D., 2013. A multicenter open-label phase II study of the efficacy and safety of ganitumab (AMG 479), a fully human monoclonal antibody against insulin-like growth factor type 1
receptor (IGF-1R) as second-line therapy in patients with recurrent platinum-sensitive ovarian cancer. Journal of Clinical Oncology, 31(15) Suppl, pp. 5515-5515.
Murphy, K.J., Elit, L., 2013. Cervical screening guidelines — discordance discussed [eletter]. CMAJ; 2013 Mar. 22.
Schwartz, L., Hunt, M., Sinding, C., Elit, L., Redwood-Campbell, L., Adelson, N., de Laat, S., and Ranford, J., 2013. La déontologie des activités cliniques occidentales est-elle applicable aux contextes humanitaires a l'étranger?. In: Abu-Sada C, ed. Jeux de miroir: Réflexions sur MSF et l'action humanitaire. Lausanne, Switzerland: Antipodes:77-92.
Lewis, G.H., DeScipio, C., Murphy, K.M., Haley, L., Beierl, K., Mosier, S., Tandy, S., Cohen, D.S., Lytwyn, A., Elit, L. and Vang, R., 2013. Characterization of androgenetic/biparental mosaic/chimeric conceptions, including those with a molar component: morphology, p57 immnohistochemistry, molecular genotyping, and risk of persistent gestational trophoblastic disease. International Journal of Gynecological Pathology, 32(2), pp.199-214.
O'Leary, E., Elit, L., Pond, G. and Seow, H., 2013. The wait time creep: Changes in the surgical wait time for women with uterine cancer in Ontario, Canada, during 2000–2009. Gynecologic oncology, 131(1), pp.151-157.
Goodwin, R.A., Jamal, R., Tu, D., Walsh, W., Dancey, J., Oza, A.M., Elit, L. and Eisenhauer, E.A., 2013. Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer. Gynecologic oncology, 131(2), pp.315-320.
Elit, L., Charles, C., Gafni, A., Ranford, J., Gold, S.T. and Gold, I., 2012. Walking a tightrope: oncologists’ perspective on providing information to women with recurrent ovarian cancer (ROC) during the medical encounter. Supportive Care in Cancer, 20(10), pp.2327-2333.
Reade, C. and Elit, L., 2012. Trends in gynecologic cancer care in North America. Obstetrics and gynecology clinics of North America, 39(2), pp.107-129.
Reade, C.J., Riva, J.J., Busse, J.W., Goldsmith, C.H. and Elit, L., 2013. Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. Gynecologic oncology, 130(3), pp.674-681.
Eva Grunfeld , Rahim Moineddin, Nadia Gunraj M. Elisabeth del Giudice, David C. Hodgson, Janice Kwon, Laurie Elit, A population based longitudinal study of cancer screening practices of cancer survivors. Canadian Family Physician 2012;58(9);980-6
Elit L, Lee A, Swynstun L, Liaw P, Julian J, Hoskins P, Parpeer S, Julian D, Levine M. Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: a phase II randomized study. Thrombosis Research 2012, 130(6)894-900
Jason E. Dodge, Allan L. Covens, Christina Lacchetti, Laurie M. Elit, Tien Le, Michaela Devries-Aboud, Michael Fung Kee Fung and The Gynecologic Cancer Disease Site Group. Preoperative identification of a suspicious adnexal mass: A systematic review and meta-analysis. Gyn Onc 2012;126:157-166
Rosen, B., Dodge, J., Giede, C., Jimenez, W., Cibulska, P., Sinesat, S., Bernardini, M., Mcalpine, J., Finlayson, S., Miller, D. and Elkanah, O., 2012. Implementation of oncology surgery in Western Kenya. Canadian Medical Association Journal, 55(4), p.284.
Ginsburg, O.M., Hanna, T.P., Vandenberg, T., Joy, A.A., Clemons, M., Game, M., MacCormick, R., Elit, L.M., Rosen, B., Rahim, Y. and Geddie, W., 2012. The global cancer epidemic: opportunities for Canada in low-and middle-income countries. Canadian Medical Association Journal, 184(15), pp.1699-1704.
Elit, L., Lytwyn, A. and Akhtar-Danesh, N., 2012. Long-Term Trends in the Survival of Women with Endometrial Cancer in Canada: A Population-Based Study. Journal of Cancer Therapy, 3(05), p.853.
Kollmannsberger C, Hirte H , Siu LL, Mazurka J, Chi K, Elit L, Walsh W, Sederias J, Chen H, Eisenhauer EA, Oza AM. Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: A NCIC-CTG phase I, open-label, dose escalation study (IND 179) Annals of Oncology 2012;23(1);238-44
Elit, L.M., Lee, A.Y., Parpia, S., Swystun, L.L., Liaw, P.C., Hoskins, P., Julian, D.H., Julian, J.A. and Levine, M.N., 2012. Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: a phase II randomized study. Thrombosis research, 130(6), pp.894-900.
Grunfeld, E., Moineddin, R., Gunraj, N., Del Giudice, M.E., Hodgson, D.C., Kwon, J.S. and Elit, L., 2012. Cancer screening practices of cancer survivors Population-based, longitudinal study. Canadian Family Physician, 58(9), pp.980-986.
Schwartz, L., Hunt, M., Sinding, C., Elit, L., Redwood-Campbell, L., Adelson, N. and de Laat, S., 2012. Models for humanitarian health care ethics. Public Health Ethics, 5(1), pp.81-90.
Lawson, L., Lytwyn, A., Jang, D., Howard, M., Elit, L., Onuma, K., Klingel, M., Toor, R., Gilchrist, J., Ecobichon-Morris, A. and Smieja, M., 2012. Comparison of APTIMA HPV E6/E7 mRNA and Hybrid Capture 2 assays using wet and dry self-collected flocked vaginal swabs and PreservCyt L-Pap samples. Journal of Analytical Oncology, 1(2), pp.149-154.
Hunt, M.R., Schwartz, L., Sinding, C. and Elit, L., 2014. The ethics of engaged presence: a framework for health professionals in humanitarian assistance and development work. Developing world bioethics, 14(1), pp.47-55.
Hunt, M.R., Schwartz, L. and Elit, L., 2012. Experience of ethics training and support for health care professionals in international aid work. Public Health Ethics, 5(1), pp.91-99.
Akhtar-Danesh, N., Lytwyn, A. and Elit, L., 2012. Five-year trends in mortality indices among gynecological cancer patients in Canada. Gynecologic oncology, 127(3), pp.620-624.
Dodge, J.E., Covens, A.L., Lacchetti, C., Elit, L.M., Le, T., Devries–Aboud, M., Fung-Kee-Fung, M. and Gynecology Cancer Disease Site Group, 2012. Management of a suspicious adnexal mass: a clinical practice guideline. Current oncology, 19(4), p.e244.
Trim, K., Nagji, N., Elit, L. and Roy, K., 2012. Parental knowledge, attitudes, and behaviours towards human papillomavirus vaccination for their children: a systematic review from 2001 to 2011. Obstetrics and gynecology international, 2012.
Elit, L., Krzyzanowska, M., Saskin, R., Barbera, L., Razzaq, A., Lofters, A., Yeritsyan, N. and Bierman, A., 2012. Sociodemographic factors associated with cervical cancer screening and follow-up of abnormal results. Canadian Family Physician, 58(1), pp.e22-e31.
Covens, A.L., Dodge, J.E., Lacchetti, C., Elit, L.M., Le, T., Devries-Aboud, M., Fung-Kee-Fung, M. and Gynecology Cancer Disease Site Group, 2012. Surgical management of a suspicious adnexal mass: a systematic review. Gynecologic oncology, 126(1), pp.149-156.
Akhtar-Danesh, N., Elit, L. and Lytwyn, A., 2012. Temporal trends in the relative survival among women with cervical cancer in Canada: a population-based study. International Journal of Gynecological Cancer, 22(7), pp.1208-1213.
Gladieff, L., Ferrero, A., De Rauglaudre, G., Brown, C., Vasey, P., Reinthaller, A., Pujade-Lauraine, E., Reed, N., Lorusso, D., Siena, S. and Helland, H., 2012. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Annals of oncology, 23(5), pp.1185-1189.